Lab21 opens syphilis testing pathways to India
This article was originally published in Clinica
UK diagnostics firm Lab21 has gained its first sales representatives in India after its immunodiagnostic division signed a distribution agreement with Spectral Diagnostics for its syphilis diagnostic test kits. Spectral, which is Inverness Medical Innovations’ distribution arm in India, will supply more than 500,000 of Lab21’s TPHA kits to the Indian Healthcare market over the next 18 months – the contract is worth approximately $1.1m of revenue for Lab21. The Cambridge-based firm said that India was the first of a number of new territories in which it planned to launch over the next twelve months. Financial terms of the deal were not disclosed.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals